Could Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) Go Down After Its Newest Short Interest Report?

The stock of Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) registered a decrease of 3.59% in short interest. FOMX’s total short interest was 1.15 million shares in December as published by FINRA. Its down 3.59% from 1.20M shares, reported previously. With 171,900 shares average volume, it will take short sellers 7 days to cover their FOMX’s short positions. The short interest to Foamix Pharmaceuticals LTD. – Ordinary Shares’s float is 4.31%.

The stock decreased 4.66% or $0.2 during the last trading session, reaching $4.09. About 204,344 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has risen 14.42% since December 8, 2017 and is uptrending. It has underperformed by 1.20% the S&P500.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. The company has market cap of $222.02 million. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. It currently has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

More notable recent Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) news were published by: Nasdaq.com which released: “Week Ahead In Pharmaceuticals: 5 Stocks To Watch (KNSA, INCY, ANAB…) – Nasdaq” on September 08, 2018, also Seekingalpha.com with their article: “Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive – Seeking Alpha” published on September 13, 2018, Seekingalpha.com published: “Key events next week – healthcare – Seeking Alpha” on October 12, 2018. More interesting news about Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were released by: Seekingalpha.com and their article: “Foamix Pharma’s FMX101 well-tolerated in safety study; shares up 14% – Seeking Alpha” published on January 04, 2018 as well as Streetinsider.com‘s news article titled: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” with publication date: November 14, 2018.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.